{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:08:24Z","timestamp":1787580504571,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jinf.2024.106288","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T12:27:47Z","timestamp":1727353667000},"page":"106288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["N-protein vaccine is effective against COVID-19: Phase 3, randomized, double-blind, placebo-controlled clinical trial"],"prefix":"10.1016","volume":"89","author":[{"given":"Sevastyan O.","family":"Rabdano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellina A.","family":"Ruzanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya E.","family":"Vertyachikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriya A.","family":"Teplykh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla B.","family":"Emelyanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German O.","family":"Rudakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei A.","family":"Arakelov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliia V.","family":"Pletyukhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita S.","family":"Saveliev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna A.","family":"Lukovenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliya N.","family":"Fakhretdinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana S.","family":"Safi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina N.","family":"Zhirenkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina N.","family":"Polyakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia S.","family":"Belozerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladislav V.","family":"Klykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arina P.","family":"Savelieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksey A.","family":"Ekimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin V.","family":"Pokachalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim A.","family":"Merkulov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei M.","family":"Yudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria S.","family":"Kruchko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor A.","family":"Berzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika I.","family":"Skvortsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2024.106288_bib1","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.immuni.2021.11.016","article-title":"Antigenic drift: Understanding COVID-19","volume":"54","author":"Yewdell","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.jinf.2024.106288_bib2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S2666-5247(22)00036-2","article-title":"SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study","volume":"3","author":"Guo","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.jinf.2024.106288_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003656","article-title":"SARS-CoV-2 neutralizing antibodies: longevity, breadth, and evasion by emerging viral variants","volume":"18","author":"Tea","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.jinf.2024.106288_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102744","article-title":"Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients\u2019 subgroups","volume":"125","author":"Ferri","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jinf.2024.106288_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41541-021-00321-8","article-title":"Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters","volume":"6","author":"Jia","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jinf.2024.106288_bib6","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20211491","article-title":"Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs","volume":"41","author":"Thura","year":"2021","journal-title":"Biosci Rep"},{"key":"10.1016\/j.jinf.2024.106288_bib7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4049\/jimmunol.2100421","article-title":"Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity","volume":"207","author":"Matchett","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.jinf.2024.106288_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188605","article-title":"OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model","volume":"14","author":"Primard","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jinf.2024.106288_bib9","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.cell.2023.04.007","article-title":"The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection","volume":"186","author":"Arieta","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jinf.2024.106288_bib10","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/vaccines11040874","article-title":"Immunogenicity and in vivo protective effects of recombinant nucleocapsid-based SARS-CoV-2 vaccine Convacell\u00ae","volume":"11","author":"Rabdano","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.jinf.2024.106288_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/vaccines12010100","article-title":"Safety and immunogenicity of the Convacell\u00ae recombinant N protein COVID-19 vaccine","volume":"12","author":"Rabdano","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.jinf.2024.106288_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/microbiolres15010015","article-title":"COVID-19 epidemic process and evolution of SARS-CoV-2 genetic variants in the Russian Federation","volume":"15","author":"Akimkin","year":"2024","journal-title":"Microbiol Res"},{"key":"10.1016\/j.jinf.2024.106288_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.36233\/0372-9311-375","article-title":"Characterisation of the COVID-19 epidemic process in Moscow and search for possible determinants of the trends of the observed changes","volume":"100","author":"Gushchin","year":"2023","journal-title":"J Microbiol Epidemiol Immunobiol"},{"key":"10.1016\/j.jinf.2024.106288_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2024.106288_bib15","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/vaccines10060938","article-title":"Sputnik V effectiveness against hospitalization with COVID-19 during Omicron dominance","volume":"10","author":"Shkoda","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.jinf.2024.106288_bib16","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3390\/vaccines10111804","article-title":"Sputnik Light and Sputnik V vaccination is effective at protecting medical personnel from COVID-19 during the period of Delta variant dominance","volume":"10","author":"Sukhikh","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.jinf.2024.106288_bib17","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2024.106288_bib18","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2024.106288_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2024.106288_bib20","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1016\/j.vaccine.2021.09.052","article-title":"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359 years: an interim analysis in Indonesia","volume":"39","author":"Fadlyana","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2024.106288_bib21","first-page":"5","article-title":"N protein based vaccine against SARS-CoV-2 produces a strong T cell immune response to N Protein of novel strains","volume":"3","author":"Rabdano","year":"2022","journal-title":"MES"},{"key":"10.1016\/j.jinf.2024.106288_bib22","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/all.15663","article-title":"Treatment of COVID\u201019 patients with a SARS\u2010CoV\u20102\u2010specific siRNA\u2010peptide dendrimer formulation","volume":"78","author":"Khaitov","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jinf.2024.106288_bib23","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1080\/22221751.2020.1855945","article-title":"Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate","volume":"9","author":"Zhang","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.jinf.2024.106288_bib24","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.3390\/v14091938","article-title":"Comparison of physical and biochemical characterizations of SARS-CoV-2 inactivated by different treatments","volume":"14","author":"Yu","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jinf.2024.106288_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abp9770","article-title":"Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity","volume":"8","author":"L\u00f3pez-Mu\u00f1oz","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.jinf.2024.106288_bib26","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.74489","article-title":"SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies","volume":"11","author":"Fielding","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.jinf.2024.106288_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41590-021-01084-z","article-title":"An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease","volume":"23","author":"Peng","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jinf.2024.106288_bib28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.virol.2006.03.036","article-title":"Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients","volume":"351","author":"Peng","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.jinf.2024.106288_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247640","article-title":"Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma","volume":"16","author":"Tso","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jinf.2024.106288_bib30","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/eji.202149470","article-title":"Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients","volume":"52","author":"Hagemann","year":"2022","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jinf.2024.106288_bib31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-021-00759-1","article-title":"Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct Target Ther"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324002226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324002226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T09:02:29Z","timestamp":1733130149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324002226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0163445324002226"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106288","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.04.01.24304717","asserted-by":"object"}]},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-protein vaccine is effective against COVID-19: Phase 3, randomized, double-blind, placebo-controlled clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106288"}}